Automated Measures of Speech Intelligibility Using Brain Wave Recordings

NCT ID: NCT06402994

Last Updated: 2025-09-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-28

Study Completion Date

2025-06-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hearing loss is one of the most prevalent impairments in the world. The World Health Organization estimates that as of 2020, around 466 million people worldwide are affected by disabling hearing loss, of which 34 million are children. Without appropriate diagnosis and treatment, hearing impairment can cause difficulties with communication, learning, social-emotional functioning, employment and quality of life. Early intervention is especially important for children, for whom unaddressed hearing loss has been proven to affect speech and language development, educational attainments, and social skills. Through early detection and interventions many of these impacts can be mitigated, highlighting the importance of accurate hearing diagnostics.

Evaluation of speech intelligibility is a fundamental component of hearing assessment and rehabilitation. The current gold standard in measuring speech intelligibility relies heavily on behavioural tests. While these tests are reliable and fast in healthy adults, it is challenging to assess speech intelligibility for patients who cannot communicate clearly, such as young children. For example, behavioral tests require active participation from the patient, such as raising their hand when a sound is heard, or repeating words and sentences.

Objective measures, for instance using electro-encephalography (EEG), could overcome the current challenges in hearing assessment and do not require active participation from the patient. For example, in Flanders, all newborns are screened with an objective test where a few sensors on the head detect brainwaves in response to sounds. However, objective tests only use simple sound stimuli, such as tones or clicks, which cannot be used to measure important high-level hearing outcomes, such as speech understanding. In other words, current objective tests are used to check if a person can hear a word, but they can't indicate if the person can understand the word.

An obvious missing link in audiological practice is a diagnostic test that can measure high-level hearing outcomes such as speech understanding in an objective way. For this reason, CORGEE was developed. CORGEE uses a novel method of "neural speech tracking" to objectively measure speech intelligibility using EEG. In the current study, the efficacy and the clinical validity of the CORGEE software will be evaluated in young children with a hearing impairment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is set-up as a pre-market clinical investigation of a non-CE marked medical device. The main goal of the study is to measure the efficacy of the CORGEE software, a newly developed software application that will function as an added service in the auditory assessment and counselling by hearing care professionals for persons with (suspected) hearing-related problems.

We will evaluate the efficacy and the clinical validity of the CORGEE software by means of a within-subject cross-sectional study in infants, toddlers, kindergartners and primary school children. The study will be carried out in 90 children with (suspected) hearing impairment. Participants are recruited via four participating sites (one university hospital and three ambulatory revalidation centers) across a period of 12 months.

All participants will undergo an objective assessment of speech intelligibility based on electrophysiological responses to natural running speech, performed by their healthcare professional (HCP). Using the CORGEE device, neural tracking of the speech envelope will be investigated with and without hearing aids at different levels of speech intelligibility. With this clinical study, we aim to demonstrate an objective hearing aid benefit when listening to natural speech using EEG. Moreover, we aim to compare the objective results with behavioural measures of speech intelligibility obtained with standard-of-care assessments (speech audiometry). Additionally, by means of questionnaires we aim to determine the HCP's evaluation of the level of tolerance of the assessment for children, as well as the HCP's user experience and satisfaction with the CORGEE software. Finally, we will assess the usability of the CORGEE software as a counselling tool for persons with (suspected) hearing-related problems and their caregivers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hearing Disorders in Children Hearing Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Infants & toddlers

Children between 0 and 2,5 years of age

Electrophysiological experiment

Intervention Type OTHER

Neural envelope tracking to conversational speech at different intensities

Kindergartners

Children between 2,5 and 6 years of age

Electrophysiological experiment

Intervention Type OTHER

Neural envelope tracking to conversational speech at different intensities

Speech audiometry

Intervention Type BEHAVIORAL

Speech perception assessment at different intensities

Primary school children

Children between 6 and 12 years of age

Electrophysiological experiment

Intervention Type OTHER

Neural envelope tracking to conversational speech at different intensities

Speech audiometry

Intervention Type BEHAVIORAL

Speech perception assessment at different intensities

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electrophysiological experiment

Neural envelope tracking to conversational speech at different intensities

Intervention Type OTHER

Speech audiometry

Speech perception assessment at different intensities

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Use of the CORGEE software

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subcategory 1 (Infants \& toddlers)

* 0 - 2,5 years of age
* Bilateral hearing loss OR
* Suspicion of hearing loss (at least 1 criteria met): referred after FAIL on the new born hearing screening OR referred by the subject's paediatrician, general practitioner or otolaryngologist
* Voluntary written informed consent of the legally authorised representative
2. Subcategory 2 (Kindergartners)

* 2,5 - 6 years of age
* Going to kindergarten
* Bilateral hearing loss
* Using hearing aids regularly for at least three months
* Would be cooperative in behavioural testing
* Knowledge of Dutch (at least 1 criteria met): Dutch as mother tongue OR enrolled in Dutch speaking education
* Voluntary written informed consent of the legally authorised representative
3. Subcategory 3 (Primary school children)

* 6 - 12 years of age
* Going to primary school
* Bilateral hearing loss
* Using hearing aids regularly for at least three months
* Would be cooperative in behavioural testing
* Knowledge of Dutch (at least 1 criteria met): Dutch as mother tongue OR enrolled in Dutch speaking education
* Voluntary written informed consent of the legally authorised representative

Exclusion Criteria

* no exposure to Dutch
* known brain injuries
* acute illness
Minimum Eligible Age

0 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

KOCA vzw

Antwerp, Antwerpen, Belgium

Site Status

CAR Sint-Lievenspoort

Ghent, Oost-Vlaanderen, Belgium

Site Status

UZ Leuven

Leuven, Vlaams-Brabant, Belgium

Site Status

CAR Overleie

Kortrijk, West-Vlaanderen, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CIV-23-08-043833

Identifier Type: OTHER

Identifier Source: secondary_id

S67892

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hearing Aids and the Brain
NCT03279510 COMPLETED NA
High Frequency ABR
NCT06161857 RECRUITING